Finance

Beta
Lists
FLNA:NASDAQ
Filana Therapeutics Inc
$1.32
-7.04%
(-0.100) 1D
$1.34
+1.89% (+0.025)
After hours
Closed: Jun 10, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for FLNA...
Open
$1.42
High
$1.45
Low
$1.32
Mkt. cap
63.77M
Avg. vol.
415.17K
Volume
236.00K
52-wk high
$2.27
52-wk low
$1.16
EPS
-$1.61
Beta
-0.70
Shares outstanding
48.31M
No. of employees
19
Open
$1.42
High
$1.45
Low
$1.32
Mkt. cap
63.77M
Avg. vol.
415.17K
Volume
236.00K
52-wk high
$2.27
52-wk low
$1.16
EPS
-$1.61
Beta
-0.70
Shares outstanding
48.31M
No. of employees
19
Analyst outlook
Analyst Ratings
Based on 1 analyst giving stock ratings to FLNA in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12 month forecast
Based on 1 Wall Street analyst offering 12 month price targets for FLNA in the last 3 months.
Highest
Current $1.32
$5.00 (+278.79%)
Average
$5.00 (+278.79%)
Lowest
$5.00 (+278.79%)
News stories
From sources across the web
Profile
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam, an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials. In June 2024, the United States Department of Justice charged an advisor to company, Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. The DOJ dropped the fraud charges against Wang shortly before trial was scheduled to begin in October 2025 without giving a reason. Wikipedia
About Filana Therapeutics Inc
CEO-
Employees19
Founded1998
HeadquartersAustin, Texas, United States
SectorPharmaceutical industry
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
5.12M
3.96M
3.85M
4.54M
Cost of revenue
5.12M
3.96M
3.85M
4.54M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.98M
7.90M
5.70M
6.62M
Operating expense
8.98M
7.90M
5.70M
6.62M
Total operating expenses
14.09M
11.86M
9.55M
11.17M
Operating income
-14.09M
-11.86M
-9.55M
-11.17M
Other non operating income
-46.00K
-114.00K
39.00K
48.00K
EBT including unusual items
-44.22M
-10.81M
-12.54M
-10.33M
EBT excluding unusual items
-12.92M
-10.81M
-8.54M
-10.33M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-44.22M
-10.81M
-12.54M
-10.33M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
1.21M
1.17M
974.00K
789.00K
Interest expense
-
-
-
-
Net interest expenses
1.21M
1.17M
974.00K
789.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-13.87M
-11.73M
-9.18M
-10.92M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more